Previse Unveils Groundbreaking Study on Barrett's Esophagus Risk
Introducing Esopredict: A Breakthrough in Esophageal Health
Previse, a pioneering company in gastrointestinal health, recently published a compelling study that underscores the effectiveness of Esopredict, a cutting-edge DNA methylation test designed to identify patients with Barrett's esophagus (BE). This innovative assay predicts which patients are at risk of progressing to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC), making it a vital tool for healthcare professionals.
Key Findings from the Study
The study, published in the journal Diagnostics, highlights the analytical validation of Esopredict, reinforcing its reliability. Sarah Laun, PhD, the VP of Research and Development at Previse, commented on the findings, stating, "This analytical validation study enhances the credibility of Esopredict's earlier clinical validation. The robust results confirm the assay's analytical performance conducted in our dedicated laboratory in Baltimore." The results showcase Esopredict's impressive reproducibility and precision, with an excellent performance across various risk levels.
Importance of Early Detection
Esophageal cancer ranks among the most formidable forms of cancer globally, known for its high mortality rates. Individuals diagnosed with Barrett's esophagus are significantly more likely to develop HGD or EAC. Until the advent of Esopredict, effective prognostic testing for this progression was lacking. Esopredict not only assists gastroenterologists in stratifying individual patient risks effectively but also helps guide surveillance and treatment decisions tailored to each patient's condition.
A Closer Look at Previse and Its Mission
Founded in 2018, Previse is dedicated to addressing chronic acid reflux diseases and cancers related to the gastrointestinal tract. The company aims to enhance patient health outcomes through early detection and preventative measures. Their pioneering biomarkers, driven by advanced research from experts like Dr. Stephen Meltzer at Johns Hopkins University School of Medicine, reflect a commitment to combating the rising incidences of GI diseases, particularly esophageal cancer.
The Role of Esopredict in Treatment Strategies
Esopredict functions as a crucial DNA methylation-based test that assesses the likelihood of progression to high-grade dysplasia or esophageal adenocarcinoma in patients with Barrett's esophagus. With a turnaround time of approximately two weeks, Esopredict enables gastroenterologists to customize their treatment approaches effectively. This timely measurement can be pivotal in ensuring early intervention, improving patient prognoses.
Contact Information and Resources
For more information regarding Esopredict and detailed findings from the study, individuals can visit Previse's official website. This resource provides insights and scientific updates essential to both healthcare providers and patients alike.
Media Contact:
Rebekah Epstein
Previse's commitment to advancing gastrointestinal health through innovative solutions positions the company at the forefront of preventative care in esophageal health.
Frequently Asked Questions
What is Esopredict?
Esopredict is a DNA methylation test designed to assess the risk of progression in patients diagnosed with Barrett's esophagus.
How does Esopredict work?
The assay analyzes specific DNA methylation patterns to evaluate the likelihood of a patient developing high-grade dysplasia or esophageal adenocarcinoma.
What are the benefits of using Esopredict?
Esopredict offers gastroenterologists a reliable method for stratifying patients' risk levels, enabling informed treatment and surveillance decisions.
Who developed Esopredict?
Esopredict is developed by Previse, which collaborates with researchers from Johns Hopkins University School of Medicine.
How quickly can results from Esopredict be obtained?
The turnaround time for Esopredict results is typically around two weeks, allowing for timely treatment interventions.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.